Cambium Bio (ASX:CMB) Buyback Yield % : 0.00 (As of Jun. 20, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cambium Bio's current buyback yield was 0.00%.

Cambium Bio Buyback Yield % Historical Data

The historical data trend for Cambium Bio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Buyback Yield % Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Buyback Yield %

Get a 7-Day Free Trial

-19.96

-6.68

1.45

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Buyback Yield %

For the Biotechnology subindustry, Cambium Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Buyback Yield % falls into.

Cambium Bio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cambium Bio's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-0.031	+	0)	/	2.145059
	=	1.45%

Cambium Bio's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	2	/	0.919311
	=	0.00%

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.

Cambium Bio Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines